SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc. (NASDAQ:FGEN) (“FibroGen”), a research-based biopharmaceutical company, today reported financial results for the quarter ended March 31, 2015.
“FibroGen and its partners, AstraZeneca and Astellas, continue to make excellent progress in the global development of roxadustat for the treatment of anemia in patients with chronic kidney disease,” said Thomas B. Neff, chief executive officer of FibroGen.
Help employers find you! Check out all the jobs and post your resume.
